AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01372410
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 31.25 mcg once daily
Trial: NCT01372410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once or twice daily
Trial: NCT04496063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous followed by Placebo subcutaneous every 8 weeks
Trial: NCT01560689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day, every day
Trial: NCT02914691
Drug: Placebo identical once daily tablet treatment
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00742573
Drug: Antidepressants through Texas Medication Algorithm (TMA)
RxNorm normalized name: influenza A virus A/Texas/50/2012 (H3N2) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
Trial: NCT02552277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo administered on study days 1, 29, and 57.
Trial: NCT01270789
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administered as once daily sc injection
Trial: NCT02271997
Drug: Iron(III)carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
Trial: NCT00389233
Drug: Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate
RxNorm normalized name: ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pack will consist of 2L NRL 994 - 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets for the 2L of 2 sachets (1 x P plus 1 x C) will be dissolved in 1L of water. Each litre will be drunk within 1 hour followed by at least 500ml of any additional clear fluid.
Trial: NCT00037791
Drug: (PN-152,243)/PN-196,444
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00285402
Drug: AST-726 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03622853
Drug: Steroid (shincort)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline
Trial: NCT01067326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill per day by mouth for 4 months
Trial: NCT03441984
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRIUMEQ (Adult) administered as a, single dose, fixed dose combination (FDC) tablet - DTG 50 mg/ABC 600 mg/3TC 300 mg as 1 conventional tablet, orally as direct-to-mouth.
Trial: NCT03441984
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/ 3TC 30 mg, orally as 10 dispersible tablets
Trial: NCT01222637
Drug: CetuGEX™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04101708
Drug: Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: half-dose clarithromycin-containing bismuth quadruple regimen
Trial: NCT02962336
Drug: Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, crossover
Trial: NCT02962336
Drug: Tribenzor Tablets of Daichi Sankyo Inc, USA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, crossover
Trial: NCT00116740
Drug: APD356
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04757532
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of chlorthalidone (1 tablet) administered orally in a single dose.
Trial: NCT02205931
Drug: Antiepileptic drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
Trial: NCT01968070
Drug: LY3127760
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01968070
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01968070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01597518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2x in first 24 hours; Placebo 2x day 2--14
Trial: NCT03452306
Drug: Glucophage® Long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition
Trial: NCT03452306
Drug: Glucophage® Long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition
Trial: NCT04140058
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of 10 mL normal saline was administered.
Trial: NCT01624636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00801398
Drug: Oxymorphone IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
Trial: NCT00373178
Drug: Anti-diabetic medications
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01670019
Drug: Placebo 1-4 tablets daily
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
Trial: NCT03045042
Drug: Enzyme Replacement Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated following the decision of their doctors. The investigators are going to analyze serum samples of these patients
Trial: NCT00796120
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 or 75 mg/m\^2 will be given intravenously every 3 weeks until disease progression.
Trial: NCT02622230
Drug: Mianhuahua Flavonoids Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)
Trial: NCT02622230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match with experimental groups
Trial: NCT02949089
Drug: ACH04
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will receive the study medication in each group
Trial: NCT01562951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
Trial: NCT01677351
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03328533
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine bitartrate variable infusion with a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min).
Trial: NCT00145925
Drug: Perindopril-indapamide
RxNorm normalized name: indapamide / perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weeks of losartan or placebo with crossover to the other
Trial: NCT02938650
Drug: Nitrosomonas eutropha
RxNorm normalized name: Jatropha curcas seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
Trial: NCT00571805
Drug: varencline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/day varencline (1.0 mg BID)
Trial: NCT00571805
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT04371601
Drug: hormones
RxNorm normalized name: Other hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a moderate amount of hormone
Trial: NCT03618472
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch based placebo manufatured to mimic Metformin 850 mg
Trial: NCT01169935
Drug: Administration of intra-dermal Endorem
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, intradermal
Trial: NCT03959098
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
Trial: NCT01093534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching solifenacin placebo tablet
Trial: NCT00662779
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
Trial: NCT02164266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo daily oral administration
Trial: NCT02164266
Drug: RO6799477
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral administration of RO6799477
Trial: NCT00860821
Drug: AZD8309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution 30 mg/g, dose: 300mg bid for 3 days
Trial: NCT04563000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
Trial: NCT01868451
Drug: Doxorubicin HCL
RxNorm normalized name: doxorubicin HCl
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01786239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.
Trial: NCT00611195
Drug: propofol, remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
Trial: NCT03990038
Drug: Extended Release Capsule
RxNorm normalized name: 24 Hour Extended Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description
Trial: NCT03706950
Drug: Elpida® + 2 NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy
Trial: NCT02749656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply on the scalp psoriasis lesion twice a day
Trial: NCT01298518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo giving for 4 weeks
Trial: NCT03125213
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Match AL-3778 tablet
Trial: NCT00081874
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I.
Trial: NCT02447757
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil analgesia during delivery
Trial: NCT01798277
Drug: Medical therapy (sotalol or amiodarone)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
Trial: NCT02211352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
Trial: NCT03471871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
Trial: NCT04221035
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m2/dose
Trial: NCT03471871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
Trial: NCT00420472
Drug: mycophenolate mofetil [CellCept]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02770664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02770664
Drug: LC28-0126 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC28-0126 Dose A
Trial: NCT02770664
Drug: LC28-0126 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC28-0126 Dose B
Trial: NCT00116870
Drug: lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00819910
Drug: Placebo (Rosiglitazone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Rosiglitazone) 8mg daily for 12 weeks
Trial: NCT00819910
Drug: Placebo (Fenofibrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Fenofibrate) 145 mg daily for 12 weeks
Trial: NCT00650572
Drug: ARRY-380, HER2 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Trial: NCT00932867
Drug: Kinzal/Pritor (Telmisartan, BAY68-9291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients under daily life treatment receiving Pritor according to local drug information.
Trial: NCT02023684
Drug: control saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical bed irrigation with saline 40ml
Trial: NCT00506545
Drug: Placebo Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
Trial: NCT00389519
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day oral placebo capsule for 4 weeks
Trial: NCT05167123
Drug: Light cured tri-calcium silicate base material
RxNorm normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe
Trial: NCT03772964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be exposed to placebo, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
Trial: NCT00099515
Drug: LY041001 (HIIP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
Trial: NCT00099515
Drug: LY041001 (HIIP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
Trial: NCT00391950
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01674777
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01938040
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single preoperative dose prior to surgery
Trial: NCT02828930
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.
Trial: NCT01030679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 1 tablet once daily for 8 weeks
Trial: NCT02170870
Drug: Microlipid
RxNorm normalized name: Microlipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
Trial: NCT02170870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion will be prepared to match the appearance of Exendin 9-39
Trial: NCT01868113
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
Trial: NCT03224325
Drug: TAK-831 Tablet T2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tak-831 tablets.
Trial: NCT03224325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-831 placebo-matching suspension.
Trial: NCT01889056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution
Trial: NCT02259998
Drug: Persantin® new formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02259998
Drug: Persantin® commercial formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02693041
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
Trial: NCT01549054
Drug: 10-mg dose of E5501-P21% powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension
Trial: NCT00161447
Drug: Testosterone Gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone Gel (10 g daily
Trial: NCT01928901
Drug: administration of Sinupret Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01928901
Drug: administration of Bronchipret Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005825
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03482037
Drug: Rec 0/0438 1 mg or Rec 0/0438 2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each vial content will be administered via the catheter used for the self-catheterization
Trial: NCT03482037
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each vial content will be administered via the catheter used for the self-catheterization
Trial: NCT04442984
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: d1 Leucovorin 400 mg every two weeks
Trial: NCT03837925
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient participation for 6 weeks of treatment
Trial: NCT02772614
Drug: BIA 3-202 (200 mg)
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg powder for oral use of unlabelled BIA 3-202
Trial: NCT03521323
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos: Saline，Sham operation
Trial: NCT01606384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Trial: NCT02767375
Drug: Oxaliplatin(OXA), 5-fluorouracil (5-FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 \& 2 , IA，q4-6 Weeks